Cargando…
Challenging the FDA Black Box Warning for High Aspirin Dose With Ticagrelor in Patients With Diabetes
Ticagrelor, a novel reversible antiplatelet agent, has a Food and Drug Administration (FDA) black box warning to avoid maintenance doses of aspirin (ASA) >100 mg/daily. This restriction is based on the hypothesis that ASA doses >100 mg somehow decreased ticagrelor’s benefit in the Platelet Inh...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
American Diabetes Association
2013
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3581224/ https://www.ncbi.nlm.nih.gov/pubmed/23431005 http://dx.doi.org/10.2337/db12-0746 |